Significant differences between the two groups were also observed in concomitant medications, with higher use of beta-blockers, renin-angiotensin system inhibitors (RAASi) and angiotensin receptor-neprilysin inhibitors (ARNi) in T2D patients with eGFR 45–59 and ≥ 60 ml/min/1.73m2, mineralocorticoid receptor antagonists in T2D with eGFR ≥ 60 ml/min/1.73m2 and SGLT2i in T2D across all eGFR categories. Here, NR3C2 is linked to type 2 diabetes mellitus.